Biotechnology

Biotech By Matthew Herper

With a detailed rundown, Pfizer seeks to paint a picture of a research turnaround

Biotech By Adam Feuerstein and Matthew Herper

Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation

Biotech By Kate Sheridan

How much is a startup worth? For biotech companies, the answer is rarely public

Biotech By Kate Sheridan

Liquid biopsy startup Grail, in filing for IPO, lays out investments and plans for growth

Biotech By Adam Feuerstein

Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle

Biotech By Matthew Herper

Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment

Heavyweights By Matthew Herper

In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics — and getting results

Adam's Take By Adam Feuerstein

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Biotech By Adam Feuerstein and Damian Garde

Stunning FDA rejection signals potential new hurdles for gene therapies

Biotech By Matthew Herper

Turning Point releases positive data for targeted cancer drug, points to more rapid FDA filing

Biotech By Adam Feuerstein and Damian Garde

An expected blockbuster drug from Gilead is rejected, imperiling the biotech’s future growth

Adam's Take By Adam Feuerstein

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Biotech By Matthew Herper

Q&A: Sanofi CEO Paul Hudson on a major acquisition, long-term strategy, and Covid-19 vaccines

Biotech By Adam Feuerstein

Unity Biotechnology fails early test, raising doubts its ability to develop drugs to reverse aging symptoms

Adam's Take By Adam Feuerstein

CytoDyn is in financial and clinical distress, newly filed annual report shows

Biotech By Matthew Herper

Sanofi, aiming to speed MS treatment, to acquire Principia Biopharma for $3.68 billion

Biotech By Damian Garde

CureVac’s value soars after IPO, as Covid-19 vaccine manufacturers become biotech’s hottest companies

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies

Health By Jonathan Saltzman — Boston Globe

‘We’re going to keep going’: A new clinical trial for ALS gives patients hope

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

Biotech By Damian Garde

FDA approves first oral treatment for a rare muscle-destroying disease

Elizabeth Nabel boards conflicts of interest

Biotech By Jonathan Saltzman — Boston Globe

Hospital president wrote opinion piece critical of drug pricing efforts, but didn’t disclose role on Moderna board

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Most Read

Plasma giant Grifols to buy Silicon Valley startup targeting blood proteins for age-related diseases

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug

Antibody drugs could be one of the best weapons against Covid-19. But will they matter?

The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment?

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

All Coverage

With a detailed rundown, Pfizer seeks to paint a picture of a research turnaround

Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation

How much is a startup worth? For biotech companies, the answer is rarely public

Liquid biopsy startup Grail, in filing for IPO, lays out investments and plans for growth

Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle

Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment

In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics — and getting results

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Stunning FDA rejection signals potential new hurdles for gene therapies

Turning Point releases positive data for targeted cancer drug, points to more rapid FDA filing

An expected blockbuster drug from Gilead is rejected, imperiling the biotech’s future growth

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Q&A: Sanofi CEO Paul Hudson on a major acquisition, long-term strategy, and Covid-19 vaccines

Unity Biotechnology fails early test, raising doubts its ability to develop drugs to reverse aging symptoms

CytoDyn is in financial and clinical distress, newly filed annual report shows

Sanofi, aiming to speed MS treatment, to acquire Principia Biopharma for $3.68 billion

CureVac’s value soars after IPO, as Covid-19 vaccine manufacturers become biotech’s hottest companies

Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies

‘We’re going to keep going’: A new clinical trial for ALS gives patients hope

4 questions for neurology startups as venture investors pour millions into the field

FDA approves first oral treatment for a rare muscle-destroying disease

Hospital president wrote opinion piece critical of drug pricing efforts, but didn’t disclose role on Moderna board

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers

biotechnology

Most Read

All Coverage